- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Milena Pavlova: Treat Sleep Disorders Independently in Patients With Epilepsy
Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, says that since sleep disorders are common, it’s important to consider that sleep can be a separate symptom from epilepsy.
Sleep disorders are common in people with epilepsy, and it's important to consider that sleep disorders can be separate from epilepsy, says Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital.
Transcript
Why should sleep be treated as a separate entity from epilepsy?
The reason to address sleep as a separate entity is because these disorders are common. Well over half of the patients with epilepsy will have insomnia complaints, and that often correlates with the frequency of seizures. Sleep apnea is something that's also very common, also more common when people gain weight. And patients with epilepsy may gain weight as a result of the medication treatment and sometimes inactivity and various other things, so it is something to consider. It is important not to attribute sleepiness to the fact that the patient has epilepsy. It can be a separate symptom.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
